CASI Pharmaceuticals, Inc. (CASI)
Stock Price Chart
Key Info
| Market Cap | 237.92M |
| Revenue (ttm) | 10.21M |
| Net Income (ttm) | -46.30M |
| Shares Out | 123.92M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
Stock Quote
| Trading Day | Aug 12, 2020 |
| Last Price | $1.92 |
| Previous Close | $1.94 |
| Change ($) | -0.02 |
| Change (%) | -1.03% |
| Day's Open | 1.97 |
| Day's Range | 1.91 - 2.00 |
| Day's Volume | 325,442 |
| 52-Week Range | 1.15 - 3.82 |
More Stats
| Market Cap | 237.92M |
| Enterprise Value | 183.42M |
| Earnings Date (est) | Nov 17, 2020 |
| Ex-Dividend Date | n/a |
| Shares Outstanding | 123.92M |
| Float | 62.69M |
| EPS (basic) | -0.48 |
| EPS (diluted) | -0.40 |
| FCF / Share | -0.29 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
| Payout Ratio | n/a |
| Shares Short | 1.72M |
| Short Ratio | 9.48 |
| Short % of Float | 2.61% |
| Beta | 0.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| P/FCF Ratio | n/a |
| PS Ratio | 23.31 |
| PB Ratio | 3.35 |
| Revenue | 10.21M |
| Operating Income | -47.40M |
| Net Income | -46.30M |
| Free Cash Flow | -29.01M |
| Net Cash | 54.50M |
| Net Cash / Share | 0.44 |
| Gross Margin | 1.92% |
| Operating Margin | -464.38% |
| Profit Margin | -614.30% |
| FCF Margin | -284.19% |
| ROA | -22.31% |
| ROE | -39.94% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Buy
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.13 | - | - | - | 0.05 | 0.02 | - | 0.67 | 1.94 | 3.69 |
| Revenue Growth | - | - | - | - | 101.09% | - | - | -65.52% | -47.45% | - |
| Gross Profit | 0.20 | - | - | - | 0.04 | 0.02 | - | 0.67 | 1.94 | 3.69 |
| Operating Income | -46.96 | -27.19 | -10.75 | -9.42 | -7.15 | -26.19 | -5.74 | -4.50 | -4.57 | -7.53 |
| Net Income | -46.03 | -27.47 | -10.77 | -9.45 | -7.21 | -26.20 | -5.74 | -14.55 | -4.56 | -8.10 |
| Shares Outstanding | 95.95 | 84.75 | 61.51 | 55.87 | 32.45 | 28.60 | 26.13 | 19.06 | 11.78 | 9.68 |
| Earnings Per Share | -0.48 | -0.32 | -0.18 | -0.17 | -0.22 | -0.92 | -0.22 | -0.78 | -0.47 | -0.94 |
| Operating Cash Flow | -23.24 | -28.58 | -6.40 | -6.02 | -5.51 | -4.00 | -3.28 | -2.21 | -4.27 | -4.96 |
| Capital Expenditures | -7.05 | -1.13 | -0.93 | -0.06 | -0.03 | -0.23 | -0.04 | -0.05 | 0.05 | - |
| Free Cash Flow | -30.30 | -29.71 | -7.34 | -6.09 | -5.54 | -4.23 | -3.32 | -2.26 | -4.22 | -4.96 |
| Cash & Equivalents | 54.25 | 85.12 | 43.49 | 27.09 | 5.13 | 10.67 | 15.13 | 8.05 | 1.08 | 4.91 |
| Total Debt | - | 1.50 | 1.50 | 1.49 | 1.46 | 1.39 | - | - | - | 0.76 |
| Net Cash / Debt | 54.25 | 83.62 | 41.99 | 25.60 | 3.67 | 9.28 | 15.13 | 8.05 | 1.08 | 4.15 |
| Assets | 103 | 113 | 45.10 | 27.71 | 5.83 | 11.31 | 15.51 | 8.98 | 3.24 | 8.04 |
| Liabilities | 8.97 | 3.95 | 6.56 | 6.93 | 11.91 | 11.73 | 0.57 | 0.74 | 0.70 | 2.70 |
| Book Value | 73.00 | 109 | 38.54 | 20.78 | -6.09 | -0.42 | 14.94 | 8.24 | 2.53 | 5.33 |
Company Profile
Company Details
| Full Name | CASI Pharmaceuticals, Inc. |
| Country | United States |
| Employees | 125 |
| CEO | Wei-Wu He |
Stock Information
| Ticker Symbol | CASI |
| Stock Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Unique Identifier | NASDAQ: CASI |
| IPO Date | June 11, 1996 |
Description
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland.